Antibiotic Allergy in Pediatrics Abstract the Overlabeling of Pediatric Antibiotic Allergy Represents a Huge Burden NIH in Society

Total Page:16

File Type:pdf, Size:1020Kb

Antibiotic Allergy in Pediatrics Abstract the Overlabeling of Pediatric Antibiotic Allergy Represents a Huge Burden NIH in Society Allison Eaddy Norton, MD, a Katherine Konvinse, MS, b Elizabeth J. Phillips, MD, a, b, c, d, e Ana Dioun Broyles, MDf Antibiotic Allergy in Pediatrics abstract The overlabeling of pediatric antibiotic allergy represents a huge burden NIH in society. Given that up to 10% of the US population is labeled as penicillin allergic, it can be estimated that at least 5 million children in this country are labeled with penicillin allergy. We now understand that most of the – aDivision of Allergy, Immunology and Pulmonology, cutaneous symptoms that are interpreted as drug allergy are likely Monroe Carell Jr. Children's Hospital at Vanderbilt, and viral induced or due to a drug virus interaction, and they usually do not cJohn A. Oates Institute for Experimental Therapeutics and Department of Pharmacology, School of Medicine, represent a long-lasting, drug-specific, adaptive immune response to the Vanderbilt University School of Medicine, Nashville, antibiotic that a child received. Because most antibiotic allergy labels Tennessee; Departments of dDivision of Infectious Disease, Medicine and bPathology, Microbiology, and Immunology, acquired in childhood are carried into adulthood, the overlabeling of Vanderbilt University Medical Center, Nashville, Tennessee; antibiotic allergy is a liability that leads to unnecessary long-term health eInstitute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Australia; and fDivision of Allergy and care risks, costs, and antibiotic resistance. Fortunately, awareness of this Immunology, Boston Children’s Hospital, Harvard Medical growing burden is increasing and leading to more emphasis on antibiotic School, Boston, Massachusetts allergy delabeling strategies in the adult population. There is growing Dr Norton conceptualized and outlined the article, literature that is used to support the safe and efficacious use of tools such drafted the initial manuscript, and reviewed and as skin testing and drug challenge to evaluate and manage children with revised the manuscript; Ms Konvinse aided in the conception and outline of the article, drafted antibiotic allergy labels. In addition, there is an increasing understanding of sections of the article, and reviewed and revised antibiotic reactivity within classes and side-chain reactions. In summary, a the manuscript; Drs Phillips and Broyles aided better overall understanding of the current tools available for the diagnosis in conceptualizing and outlining the article, and and management of adverse drug reactions is likely to change how pediatric critically reviewed and revised the manuscript; and all authors approved the final manuscript primary care providers evaluate and treat patients with such diagnoses and as submitted and agree to be accountable for all prevent the unnecessary avoidance of antibiotics, particularly penicillins. aspects of the work. DOI: https:// doi. org/ 10. 1542/ peds. 2017- 2497 1 Accepted for publication Dec 13, 2017 Antibiotic allergy labeling leads to their third birthday. The prevalent Address correspondence to Allison Eaddy Norton, significant individual and public health carriage of these childhood allergy MD, Division of Pediatric Allergy, Immunology, consequences. Unlike vaccination, labels into adulthood perpetuates and Pulmonology, Vanderbilt Children’s Hospital, there is no systematic approach to the use of alternative antibiotics, Vanderbilt University, 2200 Children’s Way, 11215 DOT, Nashville, TN 37232. E-mail: allison.norton@ address antibiotic allergy during which are often more expensive, vanderbilt.edu routine office visits, and allergy labels less effective,– and contribute to PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, persist into adulthood. Antibiotic an increase2 4 in antibiotic-resistant 1098-4275). allergy usually comes to light when bacteria. However, studies reveal Copyright © 2018 by the American Academy of treatment is imminent, and physicians that when children are tested and/– Pediatrics often find themselves choosing or undergo drug challenging, >90% 5 7 FINANCIAL DISCLOSURE: Dr Phillips has received more expensive and time-intensive are able to tolerate the antibiotic. consultancy fees from Xcovery and BioCryst; Drs procedures, such as desensitization, Unfortunately, even when the Norton, Konvinse, and Broyles have indicated they or using higher-cost alternative diagnosis of drug allergy is excluded by have no financial relationships relevant to this antibiotics with potentially more side such procedures, not only parents but article to disclose. effects. These measures may satisfy the many providers are still8, resistant 9 to FUNDING: Ms Konvinse is supported by the National immediate need for treatment but do drug allergy delabeling. Institutes of Health (1P50GM115305, 2T32GM7347, not address the primary problem. and F30 AI131780). Dr Phillips is supported by Prescription costs are 30% to 40% 1P50GM115305-01, 1R01AI103348-01, 1P30AI110527- Antibiotic allergy labels are often higher in patients10 with suspected 01A1, 5T32AI007474-20, and 1 R13AR71267-01 from acquired because of rashes reported penicillin allergy. If just half of by parents, and most children never the children who visit a physician To cite: Norton AE, Konvinse K, Phillips EJ, et al. undergo an allergy evaluation to for acute otitis media annually Antibiotic Allergy in Pediatrics. Pediatrics. 2018; address the diagnosis. In a recent were to receive amoxicillin instead 141(5):e20172497 study, 75% of children diagnosed with of cefdinir (a common alternative penicillin allergy were labeled before prescribed for treating patients with Downloaded from www.aappublications.org/news by guest on October 1, 2021 PEDIATRICS Volume 141, number 5, May 2018:e20172497 STATE-OF-THE-ART REVIEW ARTICLE a history of penicillin allergy), the Researchers in 1 large study in the adults and children– and is as high estimated annual savings11 would United States evaluating 411 543 as 20% in those18,38 linked41 to ongoing exceed $34 million. Researchers adult and pediatric medical records medical care. An allergy to in a recent cohort study were able found that the overall incidence amoxicillin is the most32 common drug to match 51582 subjects with and of self-reported antibiotic24 allergy allergy in children. Although the without penicillin allergy at hospital was as high as 15.3%. Despite epidemiology in the United States is admission. It confirmed that patients the high number of reported cases, currently unknown, hypersensitivity who require alternative drugs, such <10% of cases– are confirmed to to clavulanic acid appears prevalent as fluoroquinolones, clindamycin,Clostridium and be allergic25 after31 testing and/or in southern Europe and26, 42,has 43 been difficilevancomycin, because of a penicillin challenge, indicating that true described in children. allergy haveStaphylococcus 23.4% more aureus allergy to antibiotics32, 33 is rare and Of ADRs in pediatric patients, –β , 14.1% more methicillin- overdiagnosed. 23% are reported to be caused by resistant , and The drug allergy box is the major non -lactam antibiotics. Although 30.1% more vancomycin-resistant place in most medical records where rarely confirmed in pediatric enterococci infections compared 4 ADRs are documented, often without studies, macrolides are reported to with controls. The accumulation of reference to the immunologic basis cause drug allergy, mostly44 benign adverse drug labels is more limiting of the reaction. This label does not cutaneous reactions. Among in populations that are susceptible typically discriminate between macrolides, the 15-membered ring to frequent infections, such as cystic – pharmacological effects, side effects, azalide (azithromycin) may be more fibrosis, particularly when drug 12 14 temporally associated observations, allergenic than clarithromycin and resistance develops. or true drug allergies, making without consistent cross-reactivity with clarithromycin, erythromycin, In this state-of-the-art review, we aim the drug allergy box subject to 34 to provide clinicians with an evidence- overestimation of true allergy risk. and other 14-membered45, 46 ring based toolbox for the diagnostic traditional macrolides. This overestimation has been workup of children with antibiotic Sulfonamide antimicrobial agents demonstrated in multiple studies in infrequently cause IgE-mediated allergy. The ultimate goal is to improve – which the initial drug allergy label was patient and provider education to symptoms in children but are known based on questionnaires and/or the address and reconcile allergy labels to cause a wide array of T-cell opinions of experienced physicians, early to prevent children from carrying mediated symptoms, most commonly but subsequent drug challenges these potentially false antibiotic allergy – mild cutaneous exanthems, but were used to disprove the majority labels into adulthood. 35 37 more severe reactions such as of them. In a large study of drug reaction with eosinophilia EPIDEMIOLOGY OF ANTIBIOTIC consecutive patients with or without ALLERGY and systemic symptoms (DRESS) a history of penicillin allergy, the rate syndrome, fixed drug eruption, of positive skin testing results in those Stevens-Johnson syndrome (SJS), who were labeled as penicillin allergic toxic epidermal necrolysis (TEN), Epidemiologic studies in children with vague histories was 1.7%, which drug-induced liver disease, and with antibiotic allergy are scarce is the same as in those without23 a cytopenia– have been reported as and fraught with inconsistencies.
Recommended publications
  • Cefditoren Pivoxil) Tablets 200 and 400 Mg
    SPECTRACEF® (cefditoren pivoxil) Tablets 200 and 400 mg. To reduce the development of drug-resistant bacteria and maintain the effectiveness of SPECTRACEF® and other antibacterial drugs, SPECTRACEF® should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION SPECTRACEF® tablets contain cefditoren pivoxil, a semi-synthetic cephalosporin antibiotic for oral administration. It is a prodrug which is hydrolyzed by esterases during absorption, and the drug is distributed in the circulating blood as active cefditoren. Chemically, cefditoren pivoxil is (-)-(6R,7R)-2,2-dimethylpropionyloxymethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxy­ iminoacetamido]-3-[(Z)-2-(4-methylthiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate. The empirical formula is C25H28N6O7S3 and the molecular weight is 620.73. The structural formula of cefditoren pivoxil is shown below: cefditoren pivoxil The amorphous form of cefditoren pivoxil developed for clinical use is a light yellow powder. It is freely soluble in dilute hydrochloric acid and soluble at levels equal to 6.06 mg/mL in ethanol and <0.1 mg/mL in water. SPECTRACEF® (cefditoren pivoxil) tablets contain 200 mg or 400 mg of cefditoren as cefditoren pivoxil and the following inactive ingredients: croscarmellose sodium, D-mannitol, hydroxypropyl cellulose, hypromellose, magnesium stearate, sodium caseinate (a milk protein), and sodium tripolyphosphate. The tablet coating contains carnauba wax, hypromellose, polyethylene glycol, and titanium dioxide. Tablets are printed with ink containing D&C Red No. 27, FD&C Blue No. 1, propylene glycol, and shellac. CLINICAL PHARMACOLOGY Pharmacokinetics Absorption Oral Bioavailability Following oral administration, cefditoren pivoxil is absorbed from the gastrointestinal tract and hydrolyzed to cefditoren by esterases.
    [Show full text]
  • Medical Review(S) Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................
    [Show full text]
  • Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and Its Application
    Infect Dis Ther (2017) 6:57–67 DOI 10.1007/s40121-016-0144-8 REVIEW Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application Juwon Yim . Leah M. Molloy . Jason G. Newland Received: November 10, 2016 / Published online: December 30, 2016 Ó The Author(s) 2016. This article is published with open access at Springerlink.com ABSTRACT infections, CABP caused by penicillin- and ceftriaxone-resistant S. pneumoniae and Ceftaroline is a novel cephalosporin recently resistant Gram-positive infections that fail approved in children for treatment of acute first-line antimicrobial agents. However, bacterial skin and soft tissue infections and limited data are available on tolerability in community-acquired bacterial pneumonia neonates and infants younger than 2 months (CABP) caused by methicillin-resistant of age, and on pharmacokinetic characteristics Staphylococcus aureus, Streptococcus pneumoniae in children with chronic medical conditions and other susceptible bacteria. With a favorable and those with invasive, complicated tolerability profile and efficacy proven in infections. In this review, the microbiological pediatric patients and excellent in vitro profile of ceftaroline, its mechanism of action, activity against resistant Gram-positive and and pharmacokinetic profile will be presented. Gram-negative bacteria, ceftaroline may serve Additionally, clinical evidence for use in as a therapeutic option for polymicrobial pediatric patients and proposed place in therapy is discussed. Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 1F47F0601BB3F2DD. Keywords: Antibiotic resistance; Ceftaroline J. Yim (&) fosamil; Children; Methicillin-resistant St. John Hospital and Medical Center, Detroit, MI, Staphylococcus aureus; Streptococcus pneumoniae USA e-mail: [email protected] L.
    [Show full text]
  • Comparative Study of 5-Day and 10-Day Cefditoren Pivoxil Treatments for Recurrent Group a Β-Hemolytic Streptococcus Pharyngitis in Children
    Hindawi Publishing Corporation International Journal of Pediatrics Volume 2009, Article ID 863608, 5 pages doi:10.1155/2009/863608 Clinical Study Comparative Study of 5-Day and 10-Day Cefditoren Pivoxil Treatments for Recurrent Group A β-Hemolytic Streptococcus pharyngitis in Children Hideaki Kikuta, Mutsuo Shibata, Shuji Nakata, Tatsuru Yamanaka, Hiroshi Sakata, Kouji Akizawa, and Kunihiko Kobayashi Pediatric Clinic, Touei Hospital, N-41, E-16, Higashi-ku, Sapporo 007-0841, Japan Correspondence should be addressed to Hideaki Kikuta, [email protected] Received 20 November 2008; Accepted 23 January 2009 Recommended by Samuel Menahem Efficacy of short-course therapy with cephalosporins for treatment of group A β-hemolytic streptococcus (GABHS) pharyngitis is still controversial. Subjects were 226 children with a history of at least one episode of GABHS pharyngitis. Recurrence within the follow-up period (3 weeks after initiation of therapy) occurred in 7 of the 77 children in the 5-day treatment group and in 1 of the 149 children in the 10-day treatment group; the incidence of recurrence being significantly higher in the 5-day treatment group. Bacteriologic treatment failure (GABHS isolation without overt pharyngitis) at follow-up culture was observed in 7 of the 77 children in the 5-day treatment group and 17 of the 149 children in the 10-day treatment group. There was no statistical difference between the two groups. A 5-day course of oral cephalosporins is not always recommended for treatment of GABHS pharyngitis in children who have repeated episodes of pharyngitis. Copyright © 2009 Hideaki Kikuta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    [Show full text]
  • Antibiotic Review
    8/28/19 Disclosure 2 E. Monee’ Carter-Griffin DNP, MA, RN, ACNP-BC Antibiotic has no financial relationships with commercial Review interests to disclose. Any unlaBeled and/or E. Monee’ Carter-Griffin, DNP, MA, RN, ACNP-BC unapproved uses of drugs or products will Be Associate Chair for Advanced Practice Nursing disclosed. University of Texas at Arlington, College of Nursing & Health Innovation Dallas Pulmonary & Critical Care, PA • Identify the general characteristics of • SusceptiBility à determine which antibiotics. antibiotics a bacteria is sensitive to • Discuss the mechanism of action, • à pharmacokinetics, and spectrum of activity MIC lowest concentration of drug that inhiBits growth of the Bacteria for the most common antiBiotic drug classes. Antibiotic Objectives • Identify commonly prescriBed antiBiotics • Trough à lowest concentration of within the drug classes including dosage Lingo drug in bloodstream range and indication for prescribing. – Collect prior to administration of • Identify special considerations for specific drug antibiotics and/or drug classes. • Peak à highest concentration of • Practice appropriate prescriBing for common drug in bloodstream bacterial infections. • Review Basic antiBiotic stewardship 3 4 principles. • Penicillins • Bactericidal or bacteriostatic • Cephalosporins • Narrow or Broad spectrum • Carbapenems General • Can elicit allergic responses Antibiotic • MonoBactam Characteristics • Affect normal Body flora Drug Classes • Macrolides • Fluoroquinolones • Sulfonamides • Tetracyclines 5 6 1 8/28/19 • Penicillins – Natural penicillins 8 – Aminopenicillins Penicillins Penicillins – Anti-staphylococcal penicillins • Mechanism of action àbactericidal à – Anti-pseudomonal penicillins interrupts cell wall synthesis 7 • Pharmacokinetics • Spectrum of Activity – Gram positive organisms Natural – Penicillin G à mostly given IM, But Natural • Streptococcus species (e.g. S. Penicillins one variation can Be given IV Penicillins pyogenes) • Poorly aBsorBed via PO • Some enterococcus species (e.g.
    [Show full text]
  • Dissertation Chengwen Teng
    Copyright by Chengwen Teng 2019 The Dissertation Committee for Chengwen Teng Certifies that this is the approved version of the following dissertation: ADVERSE DRUG REACTIONS ASSOCIATED WITH ANTIBIOTICS: AN ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM Committee: Christopher R. Frei, Supervisor Kelly R. Reveles James P. Wilson Elizabeth A. Walter Carlos A. Alvarez ADVERSE DRUG REACTIONS ASSOCIATED WITH ANTIBIOTICS: AN ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM by Chengwen Teng Dissertation Presented to the Faculty of the Graduate School of The University of Texas at Austin in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy The University of Texas at Austin December 2019 Dedication I dedicated this dissertation to my family, who have supported and loved me unconditionally. Acknowledgements I would like to thank my supervisor, Dr. Christopher Frei, for his mentoring and support. Dr. Frei has guided me in every aspect of research, including literature review, generating research ideas, research proposal writing, data analysis, interpretation of data, and manuscript writing. He is a great mentor. In addition, I express my appreciation to my dissertation committee members, Dr. Kelly Reveles, Dr. James Wilson, Dr. Elizabeth Walter, and Dr. Carlos Alvarez. Thank you for your guidance and support throughout this dissertation project. Moreover, I express my gratitude to Dr. Kirk Evoy for his guidance on manuscript writing. I would also like to thank Dr. Frei’s research group members Dr. Obiageri Obodozie-Ofoegbu, Xavier Jones, Dr. Daryl Gaspar, Kaitlin Kennedy, Taylor Patek, Courtney Baus, Dr. Lindsey Groff, Dr. Victor Encarnacion, and Dr. Huda Razzack. I really appreciate your kind help.
    [Show full text]
  • WO 2010/025328 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 4 March 2010 (04.03.2010) WO 2010/025328 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US2009/055306 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 28 August 2009 (28.08.2009) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/092,497 28 August 2008 (28.08.2008) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): FOR¬ GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, EST LABORATORIES HOLDINGS LIMITED [IE/ ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, —]; 18 Parliament Street, Milner House, Hamilton, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, Bermuda HM12 (BM).
    [Show full text]
  • Cephalosporins Can Be Prescribed Safely for Penicillin-Allergic Patients ▲
    JFP_0206_AE_Pichichero.Final 1/23/06 1:26 PM Page 106 APPLIED EVIDENCE New research findings that are changing clinical practice Michael E. Pichichero, MD University of Rochester Cephalosporins can be Medical Center, Rochester, NY prescribed safely for penicillin-allergic patients Practice recommendations an allergic reaction to cephalosporins, ■ The widely quoted cross-allergy risk compared with the incidence of a primary of 10% between penicillin and (and unrelated) cephalosporin allergy. cephalosporins is a myth (A). Most people produce IgG and IgM antibodies in response to exposure to ■ Cephalothin, cephalexin, cefadroxil, penicillin1 that may cross-react with and cefazolin confer an increased risk cephalosporin antigens.2 The presence of of allergic reaction among patients these antibodies does not predict allergic, with penicillin allergy (B). IgE cross-sensitivity to a cephalosporin. ■ Cefprozil, cefuroxime, cefpodoxime, Even penicillin skin testing is generally not ceftazidime, and ceftriaxone do not predictive of cephalosporin allergy.3 increase risk of an allergic reaction (B). Reliably predicting cross-reactivity ndoubtedly you have patients who A comprehensive review of the evidence say they are allergic to penicillin shows that the attributable risk of a cross- U but have difficulty recalling details reactive allergic reaction varies and is of the reactions they experienced. To be strongest when the chemical side chain of safe, we often label these patients as peni- the specific cephalosporin is similar to that cillin-allergic without further questioning of penicillin or amoxicillin. and withhold not only penicillins but Administration of cephalothin, cepha- cephalosporins due to concerns about lexin, cefadroxil, and cefazolin in penicillin- potential cross-reactivity and resultant IgE- allergic patients is associated with a mediated, type I reactions.
    [Show full text]
  • Pharmacy Update: Truth and Consequences of Beta-Lactam Allergy Management
    Pharmacy Update: Truth and Consequences of Beta-Lactam Allergy Management Penicillin (PCN) Allergy Background o PCN allergy is the most common drug-class allergy reported - ~8-12% of patients self-report a PCN allergy - Reported anaphylactic reaction to PCN commonly precludes prescribers from using β-lactams in these patients o 80-90% of patients reporting a PCN allergy will have a negative response to PCN skin testing Impact of Penicillin Allergies o Penicillin “allergies” lead to: - More costly, less effective therapy o Longer length of stay, more medications used, more treatment failures - Worse clinical outcomes o Increased mortality, more treatment failures - 2nd and 3rd line antibiotics commonly substituted for β-lactams in patients with a penicillin “allergy” o Suboptimal use of fluoroquinolones, clindamycin, vancomycin, and aztreonam (e.g. vancomycin for MSSA) o Macy et al. J Allergy Clin Immunol: - Significantly more fluoroquinolone, clindamycin, and vancomycin use - 23.4% more C. difficile (95% CI: 15.6%-31.7%) - 14.1% more MRSA (95% CI: 7.1%-21.6%) - 30.1% more VRE infections (95% CI: 12.5%-50.4%) The Myth of Cross-Reactivity between Penicillins & Cephalosporins o The widely quoted cross-reactivity rate of 10% was originally reported in the 1960s, studies were flawed due to cephalosporins being frequently contaminated with penicillin o More recent observational studies have Table 1. FDA-approved Beta-lactam Antibiotics with Similar Side Chainsa found cross-reactivity rates between 0.17% Agent Agents with Similar Side Chains
    [Show full text]
  • RESPIRATORY TRACT RELATED INFECTIOUS SYNDROMES Acute
    RESPIRATORY TRACT RELATED INFECTIOUS SYNDROMES Acute or Acute on Chronic Bronchitis Antibiotics are NOT RECOMMENDED as >99% of acute bronchitis is caused by viruses. Asthma Exacerbation Supportive care. Antibiotics are NOT RECOMMENDED in the absence of pneumonia. COPD Exacerbation (COPDE) without evidence of pneumonia Per GOLD Guidelines, only the following patients presenting with COPDE may benefit from antibiotics - Increased sputum purulence WITH increased dyspnea or sputum volume - Severe exacerbation requiring invasive or non-invasive (e.g. BIPAP) mechanical ventilation - Pneumonia as indicated by symptoms and imaging findings Common causative pathogens: S. pneumoniae, H. influenzae, M. catarrhalis, viruses Antibiotics, in order of preference Comments Doxycycline 100 mg PO/IV BID x 5 days Has MRSA and atypical activity, some anti-inflammatory effects, may be protective against C. difficile Azithromycin 500 mg PO/IV Q24 x 5 days Has atypical activity Some anti-inflammatory effects Levofloxacin* 750 mg PO/IV Q24 x 3-5 days Increased risk of C. difficile and MRSA Black box warning for tendonitis, especially if >60 years old or concomitant steroids *Routine use levofloxacin is discouraged. Levofloxacin may be considered in patients at high risk of adverse events from COPDE such as those with poor baseline functional status, >3 exacerbations/year, FEV1 <50%. PNEUMONIA Signs/symptoms: cough +/- purulent sputum, shortness of breath, hypoxia/hypoxemia, fever >38⁰C, leukocytosis, wheezing, diminished breath sounds, pleuritic chest pain, rales/rhonchi,
    [Show full text]
  • Vs. Long-Course Antibiotic Treatment for Acute Streptococcal Pharyngitis: Systematic Review and Meta-Analysis of Randomized Controlled Trials
    antibiotics Review Short- vs. Long-Course Antibiotic Treatment for Acute Streptococcal Pharyngitis: Systematic Review and Meta-Analysis of Randomized Controlled Trials Anna Engell Holm * , Carl Llor, Lars Bjerrum and Gloria Cordoba Research Unit for General Practice and Section of General Practice, Department of Public Health, Øster Farimagsgade 5, 1014 Copenhagen, Denmark; [email protected] (C.L.); [email protected] (L.B.); [email protected] (G.C.) * Correspondence: [email protected]; Tel.: +45-261-110-54 Received: 9 September 2020; Accepted: 21 October 2020; Published: 26 October 2020 Abstract: BACKGROUND: To evaluate the effectiveness of short courses of antibiotic therapy for patients with acute streptococcal pharyngitis. METHODS: Randomized controlled trials comparing short-course antibiotic therapy ( 5 days) with long-course antibiotic therapy ( 7 days) for patients with ≤ ≥ streptococcal pharyngitis were included. Two primary outcomes: early clinical cure and early bacterial eradication. RESULTS: Fifty randomized clinical trials were included. Overall, short-course antibiotic treatment was as effective as long-course antibiotic treatment for early clinical cure (odds ratio (OR) 0.85; 95% confidence interval (CI) 0.79 to 1.15). Subgroup analysis showed that short-course penicillin was less effective for early clinical cure (OR 0.43; 95% CI, 0.23 to 0.82) and bacteriological eradication (OR 0.34; 95% CI, 0.19 to 0.61) in comparison to long-course penicillin. Short-course macrolides were equally effective, compared to long-course penicillin. Finally, short-course cephalosporin was more effective for early clinical cure (OR 1.48; 95% CI, 1.11 to 1.96) and early microbiological cure (OR 1.60; 95% CI, 1.13 to 2.27) in comparison to long-course penicillin.
    [Show full text]
  • Updates in Antibiotic Therapy for Common Illnesses
    UPDATES IN ANTIBIOTIC THERAPY FOR COMMON ILLNESSES AMY BROOKS, PHARMD, BCPS CLINICAL PHARMACIST CONCORD HOSPITAL CONCORD, NH DISCLOSURES I HAVE NO FINANCIAL RELATIONSHIPS TO DISCLOSE I WILL BE DISCUSSING DOSING AND INDICATIONS OF ANTIBIOTICS THAT MAY NOT BE FDA APPROVED OBJECTIVES • Explain basic pharmacology of major antibiotic drug classes • Develop an understanding of why certain antibiotics are used for certain disease states • Discuss first-line antibiotic choices for common disease states • Discuss circumstances in which alternative antibiotics would be necessary BACKGROUND • Studies have shown that up to 50% of all antibiotics prescribed are inappropriate.1 • Leads to increased morbidity, mortality, cost, and bacterial resistance1 • The spread of resistant bacteria can affect patients who were not even exposed to the antibiotics.2 • The CDC estimates that more than 2 million people are infected with antibiotic resistant bacteria yearly, leading to approximately 23,000 deaths each year. 2 BACKGROUND • 262.5 million antibiotics prescribed in the outpatient setting each year3 • Outpatient prescribing practices affect local resistance patterns3 • Prescribing practices vary by state and season3 • Azithromycin and amoxicillin are the most commonly prescribed outpatient antibiotics3 ANTIBIOTIC DRUG CLASSES • Penicillins • Cephalosporins • Carbapenems • Fluoroquinolones • Macrolides • Clindamycin • Glycopeptides (vancomycin) • Daptomycin • Linezolid BASIC ANTIBIOTIC PRINCIPLES • Dose matters (pharmacokinetics) • The location of the infection
    [Show full text]